Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Dec 27, 2021 10:24pm
85 Views
Post# 34264839

RE:RE:RE:RE:Whalewatcher1 when you're going for the jugular don't miss!

RE:RE:RE:RE:Whalewatcher1 when you're going for the jugular don't miss!

 What I’ve said does make sense. What you are not proving or showing is where in the entire document does it require the market cap to be $15 Million PRIOR TO an uplist? It DOESN'T. You are inserting your thought or belief into a document where no such language exists. I'll concede to you the income part which like I said is $750K NOT $1 Million. However, you are still looking at the wrong columns. PAGE 11 is the ONLY page that applies to Algernon under the Initial Listing Guide. I was making it harder for Algernon  to meet the requirements. The "Equity Standard" eliminates the "income" requirement altogether. Thus, as I keep saying, the $15 Million USD threshold is for the actual uplist. Meaning, the company cannot be valued at less than $15M USD for the IPO. It's not a multiyear look back requirement. Algernon could have traded with a value less than $1 million USD. it's irrelevant moving forward with an IPO. Also, Algernon won't just be throwing numbers up against a wall with a valuation. Nasdaq has its own mechanisms in place to determine whether or not a company can meet the valuation threshold. Anyone who believes Algernon should be trading on Nasdaq for less than $15 million market cap @ is delusional at best.


Furthermore, I believe the "income" requirement can be bypassed. I have watched a company for a year come out of bankruptcy on the OTC exchange with 3.5 Billion Outstanding Shares. The company was trading at less than a penny a share (.003) when it reverse split 1 for 4000 and did an IPO at $12 per share. That was all within 10 Days of applying to uplist. Now how in  the hell did they qualify under the Nasdaq guidelines? I'll tell you how. They obviously know more than the average person who trades on the CSE and OTC. All the more reason to get the hell off CSE and OTC ASAP or continue dying a slow and painful death by fire sale dilution and the penny flippers who give a rats @ss about due diligence or market caps/math. To them, it's all about the next chump change penny ante stock flip. Bring on the sophisticated investors and analysts at Nasdaq that Christopher Moreau rants about in writing. It can't happen soon enough.

 
<< Previous
Bullboard Posts
Next >>